Altimmune Appoints Richard Eisenstadt As Chief Financial Officer - Quick Facts

Biopharmaceutical company Altimmune, Inc. (ALT) announced Monday the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. Eisenstadt succeeds Will Brown, who is leaving Altimmune to pursue other opportunities.

Eisenstadt, who brings in 30 years of extensive experience in financing and managing drug development and commercial operations, joins Altimmune from Aytu BioPharma, Inc., where he served as Chief Financial Officer following its merger with Neos Therapeutics, Inc. in March 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration or FDA has urged infant formula manufacturers to import infant formula products to the United States to meet the ongoing severe supply shortage. In order to further increase the availability of infant formula in the country, while protecting the health of infants, the regulator announced a guidance outlining increased flexibilities for the global manufacturers Retail giant Walmart Inc. reported Tuesday a profit for the first quarter of fiscal 2023 that declined 24.8 percent from last year, hurt by lower gross margins and net losses on equity investments. Adjusted earnings per share also missed analysts' expectations, but quarterly revenues topped it. The retailer also cut its earnings guidance for the second quarter and for the full-year 2023. Billionaire and Tesla CEO Elon Musk, who is in deal to acquire Twitter Inc., may seek a lower price for the social media platform as he estimates that there could be at least four times more fake accounts than what the company informed, Reuters reported. It was in late April that Twitter agreed to accept Musk's about $44 billion takeover offer and to become a privately held company.
Follow RTT